hiv self-testing

HIV self-testing

A/Prof Rebecca Guy

Surveillance, Evaluation and Research Program

The Kirby Institute, UNSW Australia

HIV testing rates

• Guidelines (STIGMA)

– Annual testing in all gay and bisexual men (GBM)

– 3-6 monthly testing in higher-risk GBM

• GBM– 87% GBM ever tested (GCPS)

– 53% GBM re-test in 12 months (ACCESS NSW 2014)

– 54% higher risk men re-test in 6 months (ACCESS NSW 2014)

– 10-12% HIV undiagnosed (Holt 2014; Mallitt 2012)

– 31% infections transmitted by undiagnosed GBM (Wilson 2009)

• People from CALD background– 50% surveyed in NSW ever tested (CALD survey)

• Early diagnosis and treatment can reduce population incidence (Jannson 2014)

Reasons for not testing - GBM

TAXI Study 2013

Reasons for not testing - CALD

0%

10%

20%

30%

40%

50%

60%

I have always had asteady partner

I do not like havingblood tests

I am scared of gettinga positive HIV test

result

I have done nothingthat would put me at

risk

I do not like having adiscussion with the

doctor about gettingtested

I do not likeneedles/syringes

It is difficult to findthe time to get tested

It costs too much

Males Females

Potential benefits

• Public health benefit if (Guy 2015):

– Any additional HIV test due to self-test

– Previously untested men use self-test

• Partner testing

– >80% higher-risk GBM would test a partner using self-test if available (Carballo-Die´guez 2012)

– 100 sexual partners tested, 10 HIV infections diagnosed, 6 were unaware of their infections

– Very few problems occurred (Carballo-Die´guez 2012)

– 57% Australian GBM likely to test a partner (FORTH)

Perceived interest

Australian GBM

More likely to test if self-test available (GCPS 2011)

46%

Likely to test more frequently if self-test available (Bavinton 2013; Chen 2010)

63-67%

Likely to purchase self-test if available (TAXI

2013)

71%

Likely to purchase self-test from chemist (FORTH 2014-15)

86%

HST acceptability

• Systematic reviews (Krause 2013; Pant Pai 2013):

– High acceptability in a range of settings, particularly for oral fluid self-testing

– Participants found self-testing easy/very easy to perform

– Majority would recommend to others

• Very little/no evidence of harm with self-testing (Brown 2014)

TGA requirements:

• Proposed TGA requirements:

– Sensitivity: ≥99.5% whole blood, ≥99% oral fluid

– Specificity: ≥99%

TGA requirements:

• However, it is recognised that the same level of sensitivity and specificity may not be achieved in a self-testing environment.

• The suitability of these studies will be assessed on a case-by-case basis and will depend on how well the manufacturer has mitigated any risks and demonstrated that the overall benefits of the product outweigh any residual risks associated with its use. Demonstration of the benefit of a test and effectiveness of risk mitigation measures in the self-testing environment may be supported by a documented review of relevant published literature

TGA requirements:

1. The specimen collection process must be straightforward 2. The test must be easy to perform 3. Clear and simple instructions on how to perform and interpret the test4. Clear warnings on the risk of false negative results if testing is

performed in the 'window period' (and a clear explanation of what the window period is)

5. Clear indication that HIV self-testing is for presumptive screening only and the need to consult a medical practitioner for confirmatory testing of positive results by a laboratory test

6. How to contact locally available support and counselling services including phone lines and websites.

7. Information on behaviour that may place an individual at an increased risk for HIV infection and the need to test frequently if there is an ongoing risk, including a warning that a negative result does not indicate that engaging in high risk behaviour is safe

8. Information to promote safe sex and safe injecting practices and the need for individuals engaging in high risk behaviours to undergo testing for other sexually transmitted infections and blood borne viruses.

Approved HSTs (not in Australia)

OraQuick In-Home HIV test (OraSure Technologies, Bethlehem, PA, USA) approved by the FDA in 2012

BioSure HIV Self Test (BioSURE, UK, Ltd)

first CE marked self-test in the UK

Possible others in the future…

OraQuick vs BioSure

OraQuick BioSure

Device 2nd gen 2nd gen

Specimen Oral fluid Finger-prick

Sensitivity 99.3% (98.4-99.7) 99.7% (98.9-100)

Window period 3 months* 3 months*

Specificity 99.8% (99.6-99.9) 99.9% (99.6-100)

Field evaluations (untrained users)

Sensitivity 91.7% (84.24-96.33) N/A

Specificity 99.98% (99.89-100) N/A

Performance if 10,000 self-tests performed

Positivity True Positive False Positive

High (2.0%) 200 2 (1:100)

Low (0.2%) 20 2 (1:10)

*25-35 days based on published studies (Branson 2011)

Linkage to care and surveillance

• OraSure’s unobserved user study

– No serious adverse events

– 96% of HIV positive said they would follow-up with a doctor or clinic

Supplementing vs replacing

• If self-testing replaced clinic-based testing HIV prevalenceamong GBM will increase (Katz 2014)

• HOWEVER…….

• Interviews with Australian GBM, self-testing is seen as: (FORTH;

Bilardi 2013)

– Supplemental to existing testing routine

– Avenue for more frequent testing

– 92% GBM would get STI check-up at about the same or higher frequency when they get access to self-tests

Cost

• OraQuick: US$40 (plus delivery if purchased online)

• BioSure: £30 (free delivery)

• GBM in developed countries have expressed willingness to pay for self-test:

• BUT ONLY ABOUT HALF WOULD ONLY PAY $20

– Australia: 42% up to A$20 (FORTH)

– Canada: 41% up to US$20 (Pant Pai 2013)

– US: 57% up to US$20 (Katz 2012)

– Spain: 55% up to €19 (de la Fuente 2012)

– Singapore: 88% between US$7-13 (Lee 2007)

Organisations involvedKirby Institute

Melbourne sexual health clinic

Sydney sexual health clinic

Cairns sexual health clinic

CSRH

VAC

ACON

Study Design

• Does access to HIV self-testing

– Increase frequency of testing?

– Reduce STI testing?

– Acceptable?

• Wait-list control RCT (50% clinic first then switch)

• 24 months follow-up

• Sites:

– Melbourne SHC, Sydney SHC, Cairns SHC

– VAC/GMHC, ACON

• Sample size: 350 participants including 50 infrequent testers (not tested in last 2 years)

FORTH RCTRecruit high risk HIV-negative gay men

Intervention arm – given 4 test kits Deferred arm – continue with

clinic for 1 year

Baseline survey

3 months survey

6 months survey

12 months survey

Tested in clinic at baseline

Baseline survey

3 months survey

6 months survey

12 months survey

Conclusions

• HIV self-testing not yet available in Australia

• Australian GBM have expressed interested in accessing HST

• High acceptability and easy of use from overseas studies

• Potential benefits

• Acceptability studies with CALD populations?

• Delivery mechanisms/cost?